XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2019 $ 1,160     $ 4   $ 426,426 $ (425,270)
Balance (in shares) at Dec. 31, 2019   1,959,000   3,880,588,000      
Stock-based compensation 12         12  
Net loss (1,087)           (1,087)
Balance at Mar. 31, 2020 85     $ 4   426,438 (426,357)
Balance (in shares) at Mar. 31, 2020   1,959,000   3,880,588,000      
Balance at Dec. 31, 2019 1,160     $ 4   426,426 (425,270)
Balance (in shares) at Dec. 31, 2019   1,959,000   3,880,588,000      
Net loss (2,926)            
Balance at Jun. 30, 2020 3,300     $ 4   431,492 (428,196)
Balance (in shares) at Jun. 30, 2020   1,959,000   4,273,857,000      
Balance at Dec. 31, 2019 1,160     $ 4   426,426 (425,270)
Balance (in shares) at Dec. 31, 2019   1,959,000   3,880,588,000      
Balance at Dec. 31, 2020 $ 3,031     $ 7   436,535 (433,511)
Balance (in shares) at Dec. 31, 2020 6,749,028 1,954,000   6,749,028,000      
Balance at Mar. 31, 2020 $ 85     $ 4   426,438 (426,357)
Balance (in shares) at Mar. 31, 2020   1,959,000   3,880,588,000      
Stock-based compensation 43         43  
Issuance of common stock for exercise of warrants 366         366  
Issuance of common stock for exercise of warrants (in shares)       162,500,000      
Reclassification of warrant liabilities 4,264         4,264  
Issuance of common stock for in process research and development acquired from NanoTx Therapeutics 381         381  
Issuance of common stock for in process research and development acquired (in share)       230,769,000      
Net loss (1,839)           (1,839)
Balance at Jun. 30, 2020 3,300     $ 4   431,492 (428,196)
Balance (in shares) at Jun. 30, 2020   1,959,000   4,273,857,000      
Balance at Dec. 31, 2020 $ 3,031     $ 7   436,535 (433,511)
Balance (in shares) at Dec. 31, 2020 6,749,028 1,954,000   6,749,028,000      
Stock-based compensation $ 107         107  
Sale of common stock, net 7,078     $ 2   7,076  
Sale of common stock, net (in shares)       2,534,879,000      
Conversion of Convertible Preferred Stock into common stock (share)     (2,000)   118,000    
Issuance of common stock for exercise of warrants 2,017     $ 1   2,016  
Issuance of common stock for exercise of warrants (in shares)       896,500,000      
Net loss (2,720)           (2,720)
Balance at Mar. 31, 2021 9,513     $ 10   445,734 (436,231)
Balance (in shares) at Mar. 31, 2021   1,952,000   10,180,525,000      
Balance at Dec. 31, 2020 $ 3,031     $ 7   436,535 (433,511)
Balance (in shares) at Dec. 31, 2020 6,749,028 1,954,000   6,749,028,000      
Net loss $ (5,520)            
Balance at Jun. 30, 2021 $ 11,945     $ 12   450,964 (439,031)
Balance (in shares) at Jun. 30, 2021 12,087,525 1,952,000   12,087,525,000      
Balance at Mar. 31, 2021 $ 9,513     $ 10   445,734 (436,231)
Balance (in shares) at Mar. 31, 2021   1,952,000   10,180,525,000      
Stock-based compensation 138         138  
Sale of common stock, net 5,094     $ 2   5,092  
Sale of common stock, net (in shares)       1,907,000,000      
Net loss (2,800)           (2,800)
Balance at Jun. 30, 2021 $ 11,945     $ 12   $ 450,964 $ (439,031)
Balance (in shares) at Jun. 30, 2021 12,087,525 1,952,000   12,087,525,000